Skip to content
Evigrade
CriticalSNRI×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Duloxetine inhibits the reuptake of serotonin and noradrenaline (duloxetine summary of product characteristics, SmPC, European Medicines Agency, EMA) but does not inhibit monoamine oxidase (MAO) itself (duloxetine label, US Food and Drug Administration, FDA). Tranylcypromine irreversibly and non-selectively inhibits MAO A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Duloxetine can cause serotonin syndrome on its own, and the risk is higher when the regimen includes drugs that impair serotonin breakdown, such as MAO inhibitors (duloxetine SmPC, EMA). Full MAO activity returns only 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label). The elimination half-life of duloxetine is 8–17 hours, 12 hours on average (duloxetine SmPC, EMA).

Symptoms

Serotonin syndrome with tranylcypromine and duloxetine can be severe and life-threatening (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It may present with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, fever), neuromuscular abnormalities (overactive reflexes, poor coordination), nausea, vomiting or diarrhoea. In its most severe form it can resemble neuroleptic malignant syndrome, with fever, muscle rigidity, raised serum creatine kinase, rapid swings in vital signs and mental status changes (duloxetine SmPC, European Medicines Agency, EMA). The US tranylcypromine label adds tremor, myoclonus and seizures and reports fatal cases, including in people treated with tranylcypromine. It also states that when tranylcypromine interacted with serotonin and noradrenaline reuptake inhibitors, the picture sometimes resembled neuroleptic malignant syndrome (tranylcypromine label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated. The Spanish tranylcypromine summary of product characteristics (SmPC) names duloxetine among the drugs that must not be given with tranylcypromine. The European duloxetine SmPC contraindicates irreversible non-selective monoamine oxidase (MAO) inhibitors, and according to its own SmPC tranylcypromine belongs to this group (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; duloxetine SmPC, European Medicines Agency, EMA). The US tranylcypromine label lists serotonin and noradrenaline reuptake inhibitors among contraindicated products, and the US duloxetine label contraindicates MAO inhibitors intended to treat psychiatric disorders (tranylcypromine and duloxetine labels, US Food and Drug Administration, FDA). Start duloxetine at least 14 days after stopping tranylcypromine (duloxetine SmPC, EMA, and FDA label; tranylcypromine SmPC, AEMPS). Allow at least 5 days between the last dose of duloxetine and the first dose of tranylcypromine (duloxetine SmPC, EMA, and FDA label). For a switch from another antidepressant, the Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of the previous drug and its active metabolites (tranylcypromine SmPC, AEMPS). The US label gives 4–5 half-lives (tranylcypromine FDA label). If serotonin syndrome develops, stop duloxetine, tranylcypromine and any other serotonergic drug at once and start supportive symptomatic treatment (duloxetine and tranylcypromine FDA labels). Treat severe serotonin syndrome caused by an interaction as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature, and with mechanical ventilation available. For severe agitation or marked muscle rigidity, the SmPC recommends benzodiazepines, and oral cyproheptadine may be tried to block serotonin receptors. At a body temperature of 40 °C or higher, start active cooling at once (tranylcypromine SmPC, AEMPS, overdose section).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Duloxetine

Other interactions with Tranylcypromine